z-logo
Premium
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives
Author(s) -
Salem Riad,
Mazzaferro Vincenzo,
Sangro Bruno
Publication year - 2013
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.26382
Subject(s) - hepatocellular carcinoma , medicine , yttrium , radiology , oncology , medical physics , general surgery , chemistry , organic chemistry , oxide
Hepatocellular carcinoma(HCC) is the 6th most common malignancy diagnosed worldwide(1). Late stage presentation, co-morbidities, and limited donor availability enables only 10% of patients to receive curative therapies. Hence, there exists a critical need for novel treatments addressing HCC at all stages. During the last decade, several transarterial locoregional therapies have been developed. One of these, Yttrium-90(Y90) radioembolization, has matured into a recognized treatment option, with a demonstration of a clear palliative role by inducing necrosis and delaying progression(2-8). This overview will describe the biological rationale for Y90, highlight seminal data, propose research questions and discuss the future role of Y90 in HCC.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here